5-butylindanone | 165263-25-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 5-butylindanone
• 英文别名: 5-n-butylindan-1-one；5-butyl-2,3-dihydroinden-1-one
• CAS: 165263-25-2
• 化学式: C₁₃H₁₆O
• 分子量: 188.269
• InChiKey: SFMBTLFEZLQRNG-UHFFFAOYSA-N

物化性质

• 沸点：
  305.4±27.0 °C(Predicted)
• 密度：
  1.041±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-butylindanone 在 盐酸 、 亚硝酸异丁酯 、 硫酸 、 10% Pd/C 、 氢气 、 溶剂黄146 作用下， 以 甲醇 为溶剂， 25.0 ℃ 、303.99 kPa 条件下， 反应 24.0h， 生成 5-butyl-2,3-dihydro-1H-inden-2-amine
  参考文献：
  名称：

  An investigation into the structure–activity relationships associated with the systematic modification of the β2-adrenoceptor agonist indacaterol

  摘要：

  The synthesis of a series of indacaterol analogues in which each of the three structural regions of indacaterol are modified in a systematic manner is described. Evaluation of the affinity of these analogues for the beta(2)-adrenoceptor identified the 3,4-dihydroquinolinone and 5-n-butylindanyl analogues to demonstrate the most similar profiles to indacaterol. An alpha-methyl aminoindane analogue was discovered to be 25-fold more potent than indacaterol, and functional studies revealed an atypical beta(2)-adrenoceptor activation profile for this compound consistent with that of a slowly dissociating 'super agonist'. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.096
• 作为产物：
  描述：

  丁苯 在 aluminum (III) chloride 、 硫酸 作用下， 以 硝基甲烷 为溶剂， 反应 1.0h， 生成 5-butylindanone
  参考文献：
  名称：

  An investigation into the structure–activity relationships associated with the systematic modification of the β2-adrenoceptor agonist indacaterol

  摘要：

  The synthesis of a series of indacaterol analogues in which each of the three structural regions of indacaterol are modified in a systematic manner is described. Evaluation of the affinity of these analogues for the beta(2)-adrenoceptor identified the 3,4-dihydroquinolinone and 5-n-butylindanyl analogues to demonstrate the most similar profiles to indacaterol. An alpha-methyl aminoindane analogue was discovered to be 25-fold more potent than indacaterol, and functional studies revealed an atypical beta(2)-adrenoceptor activation profile for this compound consistent with that of a slowly dissociating 'super agonist'. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.096

文献信息

• [EN] QUINOLINE-2-ONE-DERIVATIVES FOR THE TREATMENT OF AIRWAYS DISEASES<br/>[FR] DERIVES DE QUINOLINE-2-ONE PERMETTANT DE TRAITER DES MALADIES DES VOIES RESPIRATOIRES
  申请人：NOVARTIS AG

  公开号：WO2004087142A1

  公开（公告）日：2004-10-14

  Compounds of formula (I) in free or salt form, wherein -C-Y-, R1 and R2 are G have the meanings as indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the (β2-adrenoreceptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  式(I)的化合物以自由形式或盐形式存在，其中-C-Y-，R1和R2是G，其含义如规范中所示，可用于治疗通过激活β2-肾上腺素受体预防或缓解的疾病。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。
• Synthesis of Indanones via Solid-Supported [2+2+2] Cyclotrimerization
  作者：Ramesh S. Senaiar、Jesse A. Teske、Douglas D. Young、Alexander Deiters

  DOI：10.1021/jo7013565

  日期：2007.9.1

  A new facile approach toward natural and unnatural indanones has been developed, featuring a solid-supported [2+2+2] cyclotrimerization as the key step. This strategy has been applied to the chemo- and regioselective assembly of indanone arrays and to the total synthesis of a recently isolated indanone marine natural product.

  已开发出一种新的简便方法来处理天然和非天然茚满酮，其中关键步骤是固相支持的[2 + 2 + 2]环三聚化。此策略已应用于茚满酮阵列的化学和区域选择性组装，以及最近分离出的茚满酮海洋天然产物的总合成。
• Quinoline-2-one derivatives for the treatment of airways diseases
  申请人：Fairhurst Alec Robin

  公开号：US20070066607A1

  公开（公告）日：2007-03-22

  Compounds of formula I free or salt form, wherein —C—Y—, R 1 and R 2 are G have the meanings as indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the β 2 -adrenoreceptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  化合物的公式为Ifree或盐形式，其中—C—Y—，R1和R2是G，其含义如规范中所示，对于预防或缓解通过激活β2-肾上腺素受体引起的病症是有用的。还描述了含有这些化合物的制药组合物和制备这些化合物的过程。
• Boberg, Friedrich; Deters, Karin; Schulz, Juergen, Phosphorus, Sulfur and Silicon and the Related Elements, 1994, vol. 91, # 1-4, p. 69 - 80
  作者：Boberg, Friedrich、Deters, Karin、Schulz, Juergen、Torges, Karl-Franz

  DOI：——

  日期：——
• Boberg Friedrich, Deters Karin, Schulz Juergen, Torges Karl-Franz, Phosph., sulfur and Silicon and Relat. Elem, 91 (1994) N 1-4, S 69-80
  作者：Boberg Friedrich, Deters Karin, Schulz Juergen, Torges Karl-Franz

  DOI：——

  日期：——